Ribokis is presented on this website as a ribociclib 200 mg product.
Therapeutic role
Ribociclib is used with endocrine therapy for selected HR-positive/HER2-negative breast cancers. Current U.S. labeling includes specified early, advanced and metastatic disease populations.
Mechanism
Ribociclib inhibits CDK4 and CDK6, which regulate progression through the cell cycle.
Reference product
KISQALI is the established ribociclib brand. It was developed by Novartis under a research collaboration with Astex Pharmaceuticals.
Safety
Important risks include neutropenia, hepatotoxicity, QT prolongation, ILD/pneumonitis, severe cutaneous reactions and embryo-fetal toxicity.
Product verification
The actual Ribokis package, manufacturer, batch information and authorization documentation should be checked before use.